Barrier dysfunction is a primary defect in Crohn’s disease (CD). The dysregulated barrier may be explained by the influence of genetics. This was shown by Keita et al. in a study with monozygotic and dizygotic twins who were discordant for CD [16]. A significant increase was observed in gut paracellular permeability in healthy monozygotic twins. It was also demonstrated that the passage of E. coli K-12 could be a consequence of inflammation rather than representing a primary defect in itself.
A total of 15 twin pairs (monozygotic n=9, dizygotic n=6) and ten external controls were included. Healthy co-twins and CD twins displayed increased 51Cr-EDTA permeability at 120 min both with (P<0.001) and without acetylsalicylic acid (P<0.001) compared to the control group. The observed difference took place at 20 min with acetylsalicylic acid when healthy co-twins were compared with external controls (P<0.05). When stratified by zygosity, an increased permeability at 20 min both with (P=0.05) and without acetylsalicylic acid (P<0.05) was observed in healthy monozygotic co-twins.
There were no statistical differences between the healthy dizygotic co-twins and external controls. Healthy monozygotic twins displayed an increased permeability at 20 min without acetylsalicylic acid when compared with healthy dizygotic co-twins (P<0.05). No difference in E. coli passage was observed between groups. Immunofluorescence of the tight junction proteins claudin-5 and tricellulin showed lower levels in healthy co-twins (P<0.05) and CD twins (P<0.05) compared with external controls. Only lower tricellulin in CD was seen compared with controls, however (P<0.05).
- Keita
V, et al. OP001. ECCO 2018.
Posted on
Previous Article
« Vedolizumab induces endoscopic remission and healing in refractory CD Next Article
Malignancies occur infrequently with tofacitinib »
« Vedolizumab induces endoscopic remission and healing in refractory CD Next Article
Malignancies occur infrequently with tofacitinib »
Table of Contents: ECCO 2018
Featured articles
IBD diagnostics
IBD disease patterns and genetics
Novel treatment strategies
Efficacy and safety of biologics
Oncology in IBD
Surgery for IBD
Related Articles
May 28, 2018
Malignancies occur infrequently with tofacitinib
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy